Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

271 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and associated with high response rates.
da Fonseca ARB, Justino CC, de Molla VC, Yamakawa PE, Rabelo IB, Arnold LM, Kelly RJ, Griffin M, Munir T, Hill A, Velloso EDRP, Dalessandro T, Risitano AM, Scheinberg P, Kulasekararaj AG, Arrais-Rodrigues C. da Fonseca ARB, et al. Blood Adv. 2024 Dec 18:bloodadvances.2024014159. doi: 10.1182/bloodadvances.2024014159. Online ahead of print. Blood Adv. 2024. PMID: 39693508
Enhanced Biodiesel Production with Eversa Transform 2.0 Lipase on Magnetic Nanoparticles.
Dos Santos KM, de França Serpa J, de Castro Bizerra V, Melo RLF, Sousa Junior PG, Santos Alexandre V, da Fonseca AM, Fechine PBA, Lomonaco D, Sousa Dos Santos JC, Martins de Souza MC. Dos Santos KM, et al. Among authors: da fonseca am. Langmuir. 2024 Dec 24;40(51):26835-26851. doi: 10.1021/acs.langmuir.4c02542. Epub 2024 Nov 26. Langmuir. 2024. PMID: 39591534 Free PMC article.
Molecular Docking and Antibacterial Activity of Campesterol Derivatives Against Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa Multiresistant Strains.
de Morais Oliveira-Tintino CD, da Silva FEF, Santiago GMP, das C L Pinto F, Pessoa ODL, da Fonseca AM, Paulo CLR, Dos Santos HS, Marinho MM, Dos Santos JL, Moura TF, Freitas PR, de Araújo ACJ, de Almeida RS, Tintino SR, Coutinho HDM. de Morais Oliveira-Tintino CD, et al. Among authors: da fonseca am. Chem Biodivers. 2025 Jan;22(1):e202401073. doi: 10.1002/cbdv.202401073. Epub 2024 Nov 8. Chem Biodivers. 2025. PMID: 39258811
Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in endemic areas of Brazil: interim results of a double-blind, randomised, placebo-controlled phase 3 trial in adolescents.
Buerger V, Hadl S, Schneider M, Schaden M, Hochreiter R, Bitzer A, Kosulin K, Mader R, Zoihsl O, Pfeiffer A, Loch AP, Morandi E Jr, Nogueira ML, de Brito CAA, Croda J, Teixeira MM, Coelho IC, Gurgel R, da Fonseca AJ, de Lacerda MVG, Moreira ED Jr, Veiga APR, Dubischar K, Wressnigg N, Eder-Lingelbach S, Jaramillo JC. Buerger V, et al. Among authors: da fonseca aj. Lancet Infect Dis. 2025 Jan;25(1):114-125. doi: 10.1016/S1473-3099(24)00458-4. Epub 2024 Sep 5. Lancet Infect Dis. 2025. PMID: 39243794 Clinical Trial.
Efficacy and safety of Butantan-DV in participants aged 2-59 years through an extended follow-up: results from a double-blind, randomised, placebo-controlled, phase 3, multicentre trial in Brazil.
Nogueira ML, Cintra MAT, Moreira JA, Patiño EG, Braga PE, Tenório JCV, de Oliveira Alves LB, Infante V, Silveira DHR, de Lacerda MVG, Pereira DB, da Fonseca AJ, Gurgel RQ, Coelho IC, Fontes CJF, Marques ETA, Romero GAS, Teixeira MM, Siqueira AM, Boaventura VS, Ramos F, Júnior EE, de Moraes JC, Whitehead SS, Esteves-Jaramillo A, Shekar T, Lee JJ, Macey J, Kelner SG, Coller BG, Boulos FC, Kallás EG; Phase 3 Butantan-DV Working Group. Nogueira ML, et al. Among authors: da fonseca aj. Lancet Infect Dis. 2024 Nov;24(11):1234-1244. doi: 10.1016/S1473-3099(24)00376-1. Epub 2024 Aug 5. Lancet Infect Dis. 2024. PMID: 39116904 Clinical Trial.
271 results